Stoke Therapeutics, Inc. (NASDAQ: STOK) opened Wednesday morning at $27.21 per share. The company priced 7 million shares of common stock at $18 per share.
JPMorgan, Cowen, Credit Suisse and Cannacord Genuity are the underwriters for the offering. As Stoke qualifies as an "emerging growth company" and a "smaller reporting company" under the federal securities laws, it has the leeway to comply with certain reduced disclosure norms.
The Massachusetts-based early-stage biopharma company was founded in June 2014 and pioneers a new way of treating underlying causes of several genetic diseases by precisely upregulating protein expression.
Stoke is developing novel antisense oligonucleotide medicines targeting RNA and modulate precursor-mRNA, developed using its proprietary technology platform names TANGO - Targeted Augmentation of Nuclear Gene Output.
Stoke shares traded around $28.64 at time of publication.
See more from Benzinga
- Rio Tinto Shares Fall On Lower Pilbara Iron Ore Shipment Guidance
- Semiconductor Maker Macom Cuts Guidance After Huawei Ban, Lays Off 250 In Restructuring
- Attention Airline Investors: Southwest Adjusts Q2 Guidance
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.